(Print or Type Responses)

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	AL
OMB Number:	3235-0287
Estimated average burd	en
hours per response	0.5

longer subject to Section 16. Form 4 or Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *- GOWER JAMES M					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						x	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X Director 10% Owner				
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 10/04/2005							X Officer (give title below) Other (specify below) CEO & Board Chairman				
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Ci		(State)	(Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Y	ear) Ex	ecuti y	emed ion Date, if /Day/Year)	Coc (Ins	Fransacti de str. 8)	(A (In	Securities Acqui ) or Disposed of other instr. 3, 4 and 5)  (A) or nount (D)	(D) Ow Tra	mount of Sec ned Following asaction(s) tr. 3 and 4)		O Fe D oi (I	wnership of orm: B irect (D) Or Indirect (I	Nature Indirect eneficial wnership nstr. 4)
			Table					tł c cquired	nis form urrently , Dispose	who respond are not requiversal of the contract valid OMB contract ed of, or Benefic vertible securiti	red to resontrol nur	pond unles nber.			SEC 14	74 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	on See (Month/Day/Year)	n Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)	4. Transac Code	4. 5. Number α  Fransaction Derivative Code Securities			f 6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect	
				Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (Right to Buy)	\$ 24.56	10/04/2005		A		200,000		11/04	/2005 <mark>(1</mark>	10/04/2015	Commo	- 1200.000	\$ 0	200,000	D	

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
GOWER JAMES M RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X		CEO & Board Chairman				

# **Signatures**

/s/ James H. Welch (Attorney-in-Fact)	10/06/2005
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The shares vest in equal monthly installments over four (4) years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.